Why the study?
Does cardiac valve replacement cause continuous in vivo platelet activation compared to healthy controls?
Does cardiac valve replacement cause continuous in vivo platelet activation compared to healthy controls?
Patients with cardiac valve prostheses show elevated levels of platelet release products at least 6 months post-surgery, suggesting continuous platelet activation regardless of valve type or site.
Elevated platelet markers post-valve replacement support ongoing activation; hypothesis-generating and should not yet change practice.
Platelets play an important role in the genesis of thromboembolic episodes frequently observed in patients following cardiac valve replacement. No simple and reliable method as yet exists for quantitating platelet function in vivo. Platelet-specific proteins, serum beta-thromboglobulin related antigen and platelet factor 4 as well as thromboxane B2 were measured in 50 healthy subjects and in 100 patients who had cardiac valve replacement at least 6 months previously; these were related to the type, site and number of valves replaced. Highly significant differences were observed in the mean plasma beta-thromboglobulin related antigen, platelet factor 4 and thromboxane B2 levels in patients compared with healthy controls. The elevated levels of platelet release products observed 6 months after cardiac valve replacement suggest a continuous activation by the prosthesis. No significant differences were observed in patients with different types and site of valve prosthesis.
No takes yet. Share an insight, caveat, or question.
Cella et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: